[1] Marks LB,Yu X,Vujaskovic Z,et al. Radiation-induced lung injury[J]. Semin Radiat Oncol,2003,13(3):333-345. DOI:10.1016/S1053-4296(03)00034-1.
[2] Mehta V. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer:pulmonary function,prediction,and prevention[J]. Int J Radiat Oncol Biol Phys,2005,63(1):5-24. DOI:10.1016/j.ijrobp.2005.03.047.
[3] Gross NJ. Pulmonary effects of radiation therapy[J]. Ann Int Med,1977,86(1):81-92. DOI:10.7326/0003-4819-86-1-81.
[4] Tsoutsou PG,Koukourakis MI. Radiation pneumonitis and fibrosis:Mechanisms underlying its pathogenesis and implications for future research[J]. Int J Radiat Oncol Biol Phys,2006,66(5):1281-1293. DOI:10.1016/j.ijrobp.2006.08.058.
[5] Weitzenblum E. Chronicforpulmonale[J]. Heart,1983,42(10):25-28. DOI:10.1136/heart.89.2.225.
[6] Rosen Ⅱ,Fischer TA,Antolak JA,et al. Correlation between lung fibrosis and radiation therapy dose after concurrent radiation therapy and chemotherapy for limited small cell lung cancer[J]. Radiology,2001,221(3):614-622. DOI:10.1148/radiol.2213992043.
[7] Storaas E,Holmaas G,Gravdal K,et al. Lethal pneumonitis after docetaxel chemotherapy:case report and review of the literature[J]. Acta Oncol,2013,52(5):1034-1038. DOI:10.3109/0284186X.2012.750734.
[8] Mangla A,Agarwal N,Carmel C,et al. Erlotinib induced fatal interstitial lung disease in a patient with metastatic non-small cell lung cancer:cCase report and review of literature[J]. Rare Tumors,2016,8(3):6410. DOI:doi:10.4081/rt.2016.6410.
[9] Chiang CL,Chen YW,Wu MH,et al. Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced nonsmall-cell lung cancer[J]. J Chin Med,2016,79(5):248-255. DOI:10.1016/j.jcma.2016.01.008.
[10] Peerzada MM,Spiro TP,Daw HA. Pulmonary toxicities of tyrosine kinase inhibitors[J]. Clin Adv Hematol Oncol,2011,9(11):824-836. ISSN 1543-0790(Print) 1543-0790(Linking).
[11] Higenbottam T,Kuwano K,Nemery B,et al. Understanding the mechanisms of drug-associated interstitial lung disease[J]. BrJ Cancer,2004,91(Suppl 2):S31-S7. DOI:10.1038/sj.bjc.6602065.
[12] 李欢欢,高宏生,魏路清. 肺泡上皮来源的血清标志物对肺纤维化的诊断价值[J]. 武警医学,2015,26(7):729-731. DOI:10.3969/j.issn.1004-3594.2015.07.026.
Li HH,Gao HS,Wei LQ. Diagnostic value of serum markers derived from alveolar epithelium for pulmonary fibrosis[J]. Armed Police Med,2015,26(7):729-731. DOI:10.3969/j.issn.1004-3594.2015.07.026.
[13] 魏路清,彭守春. 间质性肺疾病的生物学标志物研究进展[J]. 中国实用内科杂志,2014,34(8):748-751. DOI:10.7504/nk2014070104.
Wei LQ,Peng SC. Research progress on biomarkers of interstitial lung disease[J]. Chin J Pract Internal Med,2014,34(8):748-751. DOI:10.7504/nk2014070104.
[14] 周惠琼,张奉春. 涎液化糖链抗原-6在间质性肺疾病诊疗中的价值[J]. 协和医学杂志,2018,(3):207-212. DOI:CNKI:SUN:XHYX.0.2018-03-004.
Zhou HQ,Zhang FC. Value of salivary liquefied sugar chain antigen-6 in the diagnosis and treatment of interstitial lung disease[J]. Union Med J,2018,(3):207-212. DOI:CNKI:SUN:XHYX.0.2018-03-004.
[15] 刘萍,秦兴国. 间质性肺疾病治疗研究进展[J]. 国际呼吸杂志,2015,35(16):1251-1254. DOI:10.3760/cma.j.issn.1673-436X.2015.16.011.
Liu P,Qin XG. Progress in interstitial lung disease therapy[J]. Int J Respir,2015,35(16):1251-1254. DOI:10.3760/cma.j.issn.1673-436X.2015.16.011.
[16] 朱晨,赵亚滨,孔灵菲,等. 涎液化糖链抗原-6在不同类型的弥漫性间质性肺疾病患者血清和支气管肺泡灌洗液中的表达及临床意义[J]. 中华结核和呼吸杂志,2016,39(2):93-97. DOI:10.3760/cma.j.issn.1001-0939.2016.02.004.
Zhu C,Zhao YB,Kong LF,et al. Expression and clinical significance of salivary liquefied sugar chain antigen-6 in serum and bronchoalveolar lavage fluid of patients with different types of diffuse interstitial lung disease[J]. Chin J Tubercul Respir,2016,39(2):93-97. DOI:10.3760/cma.j.issn.1001-0939.2016.02.004.
[17] 陈杰,张念,崔天盆,等. 特发性肺纤维化的生物学标志物检测应用[J]. 中华检验医学杂志,2016,39(1):68-70. DOI:10.3760/cma.j.issn.1009-9158.2016.01.017.
Chen J,Zhang N,Cui TP,et al. Detection and application of biological markers of idiopathic pulmonary fibrosis[J]. Chin J Lab Med,2016,39(1):68-70. DOI:10.3760/cma.j.issn.1009-9158.2016.01.017.
[18] 陈明,曾明,何兴轩. 肺纤维化疾病生物标志物的研究进展[J]. 中国药理学与毒理学杂志,2017,31(2):187-194. DOI:10.3867/j.issn.1000-3002.2017.02.10.
Chen M,Zeng M,He XX. Research progress on biomarkers of pulmonary fibrosis[J]. Chin J Pharmacol Toxicol,2017,31(2):187-194. DOI:10.3867/j.issn.1000-3002.2017.02.10.
[19] Travis EL. Organizational response of normal tissues to irradiation[J]. Semin Radiat Oncol,2001,11(3):184-196. DOI:10.1053/srao.2001.25243.
[20] Travis EL,Vojnovic B,Davies EE,et al. A plethysmographic method for measuring function in locally irradiated mouse lung[J]. Br J Radiol,1979,52(613):67-74. DOI:10.1259/0007-1285-52-613-67.
[21] Phillips TL. An ultrastructural study of the development of radiation injury in the lung[J]. Radiology,1966,87(1):49-54. DOI:10.1148/87.1.49.
[22] Shrivastava PN,Hans L,Concannon JP. Changes in pulmonary compliance and production of fibrosis in x-irradiated lungs of rats[J]. Radiology,1974,112(2):439-440. DOI:10.1148/112.2.439.
[23] Jackson IL,Vujaskovic Z,Down JD. Revisiting strain-related differences in radiation sensitivity of the mouse lung:recognizing and avoiding the confounding effects of pleural effusions[J]. Radiat Res,2010,173(1):10-20. DOI:10.1667/RR1911.1.
[24] Plathow C,Li M,Gong P,et al. Computed tomography monitoring of radiation-induced lung fibrosis in mice[J]. Invest Radiol,2004,39(10):600-609. DOI:10.1097/01.rli.0000138134.89050.a5.
[25] Travis EL,Down JD,Holmes SJ,et al. Radiation pneumonitis and fibrosis in mouse lung assayed by respiratory frequency and histology[J]. Radiat Res,1980,84(1):133-143. DOI:doi:10.2307/3575224.
[26] Flechsig P,Hartenstein B,Teurich S,et al. Loss of matrix metalloproteinase-13 attenuates murine radiation-induced pulmonary fibrosis[J]. Int J Radiat Oncol Biol Phys,2010,77(2):582-590. DOI:10.1016/j.ijrobp.2009.12.043.
[27] Groves AM,Johnston CJ,Misra RS,et al. Whole-lung irradiation results in pulmonary macrophage alterations that are subpopulation and strain specific[J]. Radiat Res,2015,184(6):639-649. DOI:10.1667/RR14178.1. |